In Section A, participants will obtain distinctive doses and schedules of oral ABBV-744 pill to recognize safe dosing regimen. More contributors will likely be enrolled within the discovered monotherapy dosign program. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. In https://abbv-744-brd4-inhibitor-m91346.ziblogs.com/32096173/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know